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Abstract Glucose-regulated protein 78, GRP78, is a chap-
erone protein mainly located in the endoplasmic reticulum
(ER) of normal cells. In stress conditions, GRP78 is overex-
pressed and in different cancer cell types, it is expressed at the
cell surface, whereas it stays intracellular in non-cancerous
cells. Therefore, it appears as a strategic target to recognize
malignant cells. Prostate cancer is one of the most diagnosed
cancers in men. The development of castrate resistant tumors
and the resistance to chemotherapy frequently occur. The
carboxy-terminal ER retention domain is defined by the
KDEL amino acid sequence. We developed anti-KDEL func-
tionalized polymeric nanoparticles (NPs) loaded with pacli-
taxel (Tx) to specifically target prostate cancer cells
expressing GRP78. The sensitivity to Tx in different formu-
lations was compared in three prostate cell lines: PNT1B, a
normal cell line, PC3, a cancer cell line faintly expressing
GRP78 at its surface, and DU145, a cancer cell line expressing
GRP78 at its cell surface. Our results show that the targeted
formulation significantly increases Tx sensitivity of cell line
expressing GRP78 at its surface compared to other treatments
suggesting the added value of GRP78 targeted therapy for
castrate resistant tumor which expresses GRP78 at its cell
surface.
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Introduction
Prostate cancer is the most diagnosed cancer in men in
Europe. Despite advances in therapies, the occurrence of
castrate resistant prostate cancer (CRPC) and resistance to
chemotherapy are still challenging.
GRP78 is an endoplasmic chaperone which plays a crit-
ical role in prostate cancer. this protein is primarily located
in the endoplasmic reticulum (ER) where it is a regulator of
the unfolded protein response. GRP78 expression is induced
under stress conditions such as hypoxia and glucose depri-
vation which are frequently observed in tumor microenvi-
ronment. In many type of cancer cells, GRP78 is expressed
at the cell surface, a fact not observed in normal cells [1].
Furthermore, GRP78 expression has been associated with
malignancy and drug resistance [2–6]. It has also been
shown that GRP78-knock-down greatly induces chemosen-
sitivity of growth arrested dormant cancer cells and tumor-
associated endothelial cells [7, 8]. These observations sug-
gest that inhibition or downregulation of GRP78 will be
particularly relevant to eradicate residual tumor by over-
coming drug resistance in proliferating and dormant cancer
cells, as well as in cells supporting tumor growth [1]. In
cancer cells, several proteins have been identified to bind
membrane GRP78 in its N- or C-terminus [9–14]. In pros-
tate cancer cells, activated alpha2-macroglobulin binding to
membrane GRP78 activates several signaling pathways in
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favor of proliferation and cell survival [11]. These pathways
can be suppressed by ligation of cell surface GRP78
with antibodies directed against its COOH-terminal domain
[15, 16].
GRP78 is therefore, a good pharmacological target to
inhibit cancer cell growth and spreading. Furthermore, as
exclusively expressed at cancer cell surface, GRP78 may be
a good candidate to specifically deliver drug to the cells of
interest. Targeted therapy is based on the specific recogni-
tion of a molecular entity characteristic of a designated
organ or cells to concentrate large amount of drug to the
target without inducing adverse effects related to a non-
specific distribution. To this end, a drug or a drug-loaded
carrier may be chemically linked to a ligand specific to a
molecular target overexpressed or ideally exclusively
expressed at the cells of interest. Polymeric nanoparticles
(NPs) are solid drug carriers in which the drug is encapsu-
lated in a polymeric matrix. NPs offer the advantages of
high compound loading rates, enabling the formulation of
poorly soluble drugs as fine injectable suspensions. The
surface of the nanocarriers may be functionalized with spe-
cific ligands such as antibodies, aptamers, glycoproteins,
lectines or peptides to trigger the recognition of a defined
target. Paclitaxel (Tx) is a chemotherapeutic drug of the
taxane family widely used in the treatment of advanced
and recurrent prostate cancers. It suffers from a low water
solubility necessitating the use of cosolvents such as Cre-
mophor®, responsible for severe side effects. NP formula-
tion has been proposed to circumvent the solubility problem
related to Tx. Recently; Tx-loaded NPs were functionalized
with Herceptin®, as a targeting moiety, for the delivery to
ovarian cancer cells overexpressing HER2 specific antigens.
This drug delivery system proved to be efficient in vitro and
in vivo against SKOV-3 cell model [17, 18].
In this study, we focused on the interest of anti-KDEL
antibodies as a recognition moiety for the COOH-terminal
domain of GRP78 present at cancer cell surface to specifi-
cally target cancer cells in CRPC and to increase response to
chemotherapy. Tx-loaded nanoparticles (NPs-Tx) were cou-
pled to antibodies against the KDEL sequence and studied
on different prostate cell lines viability: normal cell line,
PNT1B, castrate resistant cancer (CRC) cell line which does
not or faintly express GRP78 on its surface, PC3 and castrate
resistant cell line which expresses GRP78 at its cell surface,
DU145 [11, 19].
Materials and methods
Reagents
Poly (DL-lactic acid) (100DL 4A, MW 57 kD) was provid-
ed by Lakeshore Biomaterials, Inc (Birmingham, AL,
USA). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide
(EDAC), D(+)-Trehalose dihydrate, phosphate buffer saline
(PBS), poly-L-Lysine solution, 0.1 % (w/v) were from Sig-
ma (Buchs, Switzerland). m-maleimidobenzoyl-N-hydroxy-
sulfosuccinimide ester (sulfo-MBS), Tris (2-carboxyethyl)-
phosphine hydrochloride (TCEP) and D-salt dextran plastic
columns were supplied by Pierce (Rockford, IL, USA).
Dioctadecyloxacarbo-cyanine perchlorate (DiO) was from
Molecular Probes (Leiden, The Netherlands). Poly(vinyl
alcohol) (Mowiol 4–88) was purchased from Hoechst
(Frankfurt/M, Germany). Paclitaxel (Tx) was obtained from
Cfm Oskar Tropitzsch (Marktredwitz, Germany).
Rabbit anti-GRP78 antibodies (GL-19) were from Sigma
(Buchs, Switzerland) and mouse anti-KDEL antibodies
from Assay Designs (Ann Arbor, MI, USA). Secondary
antibodies were goat anti-mouse IgG-HRP conjugated from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and goat
anti-rabbit IgG-HRP conjugated from BIO-RAD (Munich,
Germany).
Dulbecco’s modified Eagle’s medium (DMEM), Hank’s
balanced salts, gentamycin, were products of Invitrogen
(Basel, Switzerland). Fetal bovine serum (FBS) was from
Biochrom AG (Oxoid AG, Basel, Switzerland).
Cell proliferation reagent (WST-1) was provided by
Roche Diagnostics GmbH (Indianapolis, IN, USA).
Nanoparticles
The nanoparticles were prepared by a salting-out process
and characterized as previously described [20, 21]. Briefly,
Tx was added to a solution of poly (DL-lactic acid) (PLA) in
acetone (drug to polymer ratio: 1:10). The organic phase
was mixed under vigorous stirring at 45 °C with an aqueous
phase containing 15 % (w/w) poly (vinyl alcohol) (PVAL)
used as surfactant and 60 % (w/w) magnesium chloride
hexahydrate. Then, 20 ml of pure water was added to the
NPs suspension and stirring was maintained for 10 min. NPs
were recovered by centrifugation (Optima® XL-100K, rotor
70.1 Ti Centrifuge, Beckman Coulter Inc., Fullerton, CA,
USA), washed twice with pure water to remove unencapsu-
lated drug, PVAL and magnesium salt. NPs were lyophilized
(Edwards, Modulyo, Oberwil, Switzerland) in presence of
trehalose (30 % w/w) stored at 4 °C until use.
The anti-KDEL antibodies were grafted using a carbodii-
mide method as already described [20, 21]. In a first step,
the free carboxyl groups of the polymer at the NPs surface
were thiolated to allow the covalent attachment of antibod-
ies via a sulfo-MBS (m-maleimidobenzoyl-N-hydroxy-sul-
fosuccinimide ester) cross-linker. Anti-KDEL antibodies
were, then, activated in PBS (pH 7.4) with sulfo-MBS.
After removing non-reacted sulfo-MBS by centrifugation
(3000 rpm for 15 min) using Amicon Ultra-4 centrifugal filter
devices, the activated ligand was incubated with NPs and
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gently shaken at room temperature. Unconjugated ligand was
removed by centrifugation.
The size and morphology of NPs were analysed by
photon correlation spectroscopy using a Zetasizer 3000 HS
(Malvern instruments Ltd, Worcestershire, UK), and scan-
ning electron microscopy performed on gold-coated freeze-
dried samples (Balzers SCD 004 Sputter Coater) with a
JEOL JSM-6400 microscope (JEOL, Tokyo, Japan) at an
accelerating voltage of 10 or 15 kV. Zeta potential of the
particles was obtained in a 10−3M NaCl solution using the
electrophoretic mode of the Zetasizer 3000 HS. Drug load-
ing was determined by reverse-phase HPLC with UV detec-
tion after dissolution of the polymeric matrix in acetone
[20]. The drug loading was expressed as the amount of drug
encapsulated per mg of NPs. The amount of anti-KDEL
antibodies conjugated to NPs was determined indirectly by
measuring uncoupled antibodies in the supernatant by spec-
trophotometry (λ0280 nm) (Hewlett Packard, Model 8453,
Germany) after centrifugation.
Cell culture
Prostate cell lines DU145, PC3 and PNT1B were kindly
provided by Dr P. Rocchi (Inserm 624, Marseille, France),
and grown in DMEM medium supplemented with 10 % (v/v)
foetal bovine serum, and 0.1 mg/ml gentamicin under 5 %
CO2, at 37 °C.
Cell proliferation
Prostate cancer cells were seeded in 96-well plates at a
density of 30 000 cells/well (PNT1B) or 10 000 cells/well
(PC-3 and DU145) and incubated for 24 h before treatment.
Cell culture medium was then replaced by 100 μl of the
different formulations (Tx, NPs, NPs-Tx, NPs-Tx-
KDEL, anti-KDEL or anti-KDEL with NPs-Tx) at dif-
ferent concentrations (0, 0.6, 1.2, 3.6, 6 and 60 ng/ml
equivalent Tx and/or equivalent concentration of anti-
KDEL) for 5 h before washing and replacement with culture
medium for 24 h or 48 h. In vitro cytotoxicity was then tested
on cells using 100 μl of WST-1 proliferation assay. Plates
were analyzed after 1 h using a microplate reader at λ0
450 nm. Cell viability was calculated in percent compared to
control samples incubated with normal culture medium
and set at 100 %. Each experiment was run four times in
triplicate.
Statistical analysis
Results were measured and expressed as mean ± SE.
The differences between samples were evaluated by the
Student’s t test and p value<0.05 was considered
significant.
Results-discussion
GRP78 is overexpressed and relocated at cell surface in
many cancer cells. It, thus, represents a very interesting
target to be associated with drug delivery systems, as it is
specifically expressed at cell surface of cancer cells and not
in healthy cells. Different peptide ligands of GRP78 have
already been tested to bind to the surface expressed GRP78
to be used as drug delivery systems [22–25]. The peptides
interacted with cancerous cells whereas only limited recog-
nition was observed with normal cells. The peptide-drug
conjugates were internalized in cancer cells, concentrated
in the tumor tissue without accumulation in other organs,
demonstrating the specificity of the binding and the interest
of targeting the GRP78.
Direct binding of peptide to a drug molecule is a common
way to achieve targeting. However, chemical modifications
of the active compound and the further release of the drug
may compromise the pharmacological efficiency. Therefore,
other approaches involving synthetic drug carriers, such as
liposomes and nanoparticles (NPs) have been developed.
The drug is encapsulated or associated with a polymer or
lipid core and the surface is functionalized with a recogni-
tion moiety. For instance, pegylated liposomes were surface-
modified by Katanasaka et al. [26] with a GRP-recognizing
peptide developed by Arap et al. [22]. It was shown in vitro
that the liposomes were able to target VEGF-activated
HUVEC cells as well as DU145, a prostate cancer cell line
[26]. This study confirms the interest of using GRP78 as a
target element to bring large amount of drug to a tumor via
colloidal carriers and shows that GRP78 can be also a target
for cancer antineovascularisation therapy.
So far, to our knowledge, only peptides have been used
as GRP78-recognizing entity. Despite the fact that some
GRP78 antibodies have been described as potent anti-
tumor agent [15, 16, 27], they have never been tested for
targeting therapy. As a proof of concept, Tx-loaded NPs
were functionalized with antibodies against the KDEL ami-
no acid sequence present in C-terminus of GRP78. The
influence of these particles on cell survival was compared
with other Tx formulations. Different recognition moieties
have been tested for prostate cancer nanotargeting [28–34].
Compared to the other ligands, GRP78 offers the advantage
of not only being expressed in prostate cancer cells [35] but
Table 1 Characterization of the NPs
Size
(nm)
Polydispersity
index
Paclitaxel
loading
(μg/mg)
Zeta
potential
(mV)
NPs-Tx 241 0.07 67.5 −13.2
NPs-Tx-KDEL 305 0.15 69.35 −1.5
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also on other tumors such as neuroblastoma, lung adenocar-
cinoma, colon adenocarcinoma, ovarian tumor cells [36],
proliferating endothelial cells and, more generally, stressed
tumor cells [10]. Therefore, it is more versatile target; im-
plying that, if successful, this strategy may be applied to
other cancer therapy. Furthermore, as antibodies against the
-COOH end of the GRP78 present anti-cancer activity, a
synergistic effect is expected between the loaded drug and
the targeting ligand.
The characteristics of the different NPs batches are de-
scribed in details in (Biochimie, submitted) and are summa-
rized in Table 1.
Figure 1 shows the effect of the different formulations of
Tx on the viability of three prostate cell lines expressing
Fig. 1 Cell viability after 5 h of incubation with NPs at different
concentrations (0, 3.6, 6, 60 ng/ml Tx equivalent), PNT1B (A), PC3
(B) and DU145 (C) cells were washed and cultured for 48 h before
proliferation assay was performed. Unloaded NPs were used as controls
for the possible cell toxicity of the polymer. In all cells and all concen-
trations, cells viability was not altered by the presence of unloaded NPs
(data not shown). Viability was assessed by a WST1 assay and calculated
in percent compared to control sample incubated with normal culture
medium and set at 100 %. Each experiment was run four times in
triplicate. Tx: paclitaxel; NPs-Tx: paclitaxel-loaded NPs, NPs-Tx-
KDEL: anti KDEL conjugated-paclitaxel-loaded NPs; NPs-Tx + KDEL:
paclitaxel-loaded NPs in the presence of free anti-KDEL antibodies
Fig. 2 DU145 cell viability
after 5 h incubation with NPs
at different concentrations
(3.6, 4.5, 6, 9, 60 ng/ml Tx
equivalent). Cells were washed
and cultured for 48 h before
proliferation assay was
performed. Approximate IC50
for each molecule was
determined. Tx: paclitaxel;
NPs-Tx: paclitaxel-loaded NPs,
NPs-Tx-KDEL: anti-KDEL
conjugated-paclitaxel-loaded
NPs
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differently the GRP78 at their surface: the non-cancerous
cell line, PNT1B; a CRC cell line not or faintly expressing
GRP78 at its surface, the PC3 cells and the DU145 cells, a
CRC cell line expressing GRP78 at its surface.
In the non-cancerous cell line, Tx either free or loaded in
NPs did not induce a significant toxicity and no difference
was seen between the formulations (Fig. 1a).
As expected, cancerous cells were more sensitive to the
treatment with Tx due to their higher proliferation rates.
Free Tx induced a dose-related cytotoxicity which was more
noticeable on DU145 compared to PC3 in these conditions
of treatment.
Similar effects were observed when Tx was incubated as
a suspension in NPs coated or not with anti-KDEL anti-
bodies in PC-3 cells which do not express GRP78 at their
surface (Fig. 1b). In the opposite, in DU145 cell line which
expresses GRP78 at cell surface, NPs-Tx-KDEL significantly
altered cell viability compared to Tx or NPs-Tx(Fig. 1c). In
this cell line, IC50 of Tx was decreased by about 2-fold when
Tx is loaded in NPS, and more than 4-fold when Tx-loaded
NPs were coated with anti-KDEL antibodies (Fig. 2).
It was already described that antibodies against GRP78
COOH terminus can suppress proliferative/survival signal-
ing pathways of prostate cancer cells expressing GRP78 at
their surface [16]. We thus chose monoclonal KDEL anti-
bodies to functionalize Tx-loaded NPs to target the -COOH-
terminal domain of membrane GRP78 and potently inhibit
pathways implied in cancer growth. This strategy proved
correct by making Tx more toxic in GRP78-expressing cells
when presented in targeted nanocarriers, most likely by
favoring cell penetration of the chemotoxic agent. However,
when free anti-KDEL was added to NPs-Tx in culture medi-
um, cytotoxic effects of NPs-Tx was reversed in all cell lines
suggesting an anti-apoptotic effect of these antibodies
(Fig. 1a-c).
Despite anti-apoptotic effects of anti-KDEL antibodies
on cells, this study confirms the interest of anti-cancer
therapy by targeting cell-surface GRP78 on cancer cells
which express GRP78 at cell surface, and demonstrates the
efficiency of coupling GRP78 antibodies to NPs for prostate
cancer cells.
In contrast to GRP78 autoantibodies isolated from serum
of patients with prostate cancer, we have recently purified
GRP78 autoantibodies from serum of ovarian cancer
patients with potent anti-tumoral activity suggesting their
interest for being coupled to NPs-Tx to increase response to
drug [27].
In conclusion, we confirmed that GRP78 has the poten-
tial to be used as target against prostate cancer cells express-
ing GRP78 at their surface to both specifically vehicle drug
and increase response to drug. We also demonstrated for the
first time that antibodies against GRP78 could be used to
this end.
Future prospects will include the testing of particles
coated with these antibodies and in vivo studies to further
confirm the interest of targeting nanocarriers for cancer
therapy.
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